New RIGVIR website is coming out after
in the treatment of malignant tumors
Anti-cancer drug inventor
Awarded with a certificate and Golden Medal of World Intellectual Property Organization (WIPO)
Author of more than 650 publications, including approximately 300 patents
The Rigvir Group is one of the fastest growing biopharmaceutical holdings in Northern Europe, based in Riga, the business capital of the Baltic States. The therapeutic focus area of the Rigvir Group is oncolytic virotherapy with the first registered non-modified ECHO-7 virus.
Our goal is to change the paradigm of oncology and to show the world a safe, effective and harmless drug to prevent metastasis both in early and advanced stages of cancer, including in treatment combinations with other innovative immunotherapy medication.
Our approach is not only about the envisioned potential of ECHO-7 and virotherapy. It is working already, and the lives of our patients are improving today. The future is now.